Tonix Pharmaceuticals Secures FDA Alignment on Phase 2 Lyme Disease Prevention Study for TNX-4800

summarizeSummary

Tonix Pharmaceuticals announced FDA alignment on a Phase 2 field study for TNX-4800, a Lyme disease prevention antibody, with enrollment expected to begin in Q1 2027.

check_boxKey Events · Product Development and Regulatory · TNXP

• FDA Alignment on Phase 2 Study

  Official FDA minutes confirm alignment on an adaptive Phase 2 field study for TNX-4800, a monoclonal antibody to prevent Lyme disease, with a planned enrollment of 3,300 adults over two seasons.

• Study Design and Endpoints

  The randomized, placebo-controlled study sets the primary efficacy endpoint as Lyme disease prevention at six months, with a key secondary endpoint at three months and safety evaluated over 52 weeks.

• Manufacturing and Timeline

  Investigational product manufacturing remains on track for delivery to study sites in Q1 2027; the majority of enrollment is expected in the 2028 season, with a potential extension to 2029.

• Strategic Importance

  Addressing a large unmet need — no FDA-approved Lyme disease vaccines or prophylactics exist — TNX-4800 could provide rapid, seasonal protection with a two-dose regimen.

auto_awesomeAnalysis · TNXP · Life Sciences

Receipt of official FDA minutes confirms alignment on the adaptive Phase 2 field study design for TNX-4800, a long-acting monoclonal antibody aimed at preventing Lyme disease. The trial will enroll 3,300 adults across two seasons, with the primary endpoint assessed at six months. This regulatory milestone de-risks the program and establishes a clear path toward a pivotal efficacy study, potentially addressing a large unmet need given that no Lyme disease vaccines or prophylactics are currently approved. The news carries added weight against the backdrop of a going-concern warning and cash burn — positive pipeline progress strengthens the investment thesis and could support future financing.